Bladder Cancer

1. Clinical Overview

Summary

Bladder cancer is the most common malignancy of the urinary tract and the 10th most common cancer worldwide, with approximately 573,000 new cases diagnosed annually. [1] The vast majority (90%) are urothelial (transitional cell) carcinomas arising from the bladder urothelium. The cardinal presenting symptom is painless visible haematuria, which occurs in 80-90% of cases. [2] Smoking is the dominant modifiable risk factor, contributing to approximately 50% of all cases in men and 35% in women, with dose-dependent risk that persists for decades after cessation. [3]

Bladder cancer is broadly classified into non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), with treatment strategy and prognosis differing substantially between the two. NMIBC (stages Ta, T1, and carcinoma in situ) accounts for approximately 75% of newly diagnosed cases and is managed with transurethral resection of bladder tumour (TURBT) and risk-adapted intravesical therapy using Bacillus Calmette-Guérin (BCG) or mitomycin C. [4] MIBC (stage ≥T2) requires multimodal treatment with radical cystectomy plus neoadjuvant chemotherapy or bladder-preserving trimodal therapy (TURBT, chemotherapy, and radiotherapy). [5]

Recent advances in molecular characterization have identified distinct molecular subtypes (luminal and basal) with differential responses to therapy, enabling precision oncology approaches. [6] The treatment landscape for advanced and metastatic disease has been transformed by immune checkpoint inhibitors (pembrolizumab, atezolizumab, nivolumab) and antibody-drug conjugates (enfortumab vedotin), with the EV-302 trial demonstrating significant survival benefit with enfortumab vedotin plus pembrolizumab as first-line therapy (median overall survival 31.5 months vs 16.1 months with chemotherapy alone). [7]

Key Facts

• Global incidence: 573,000 cases/year worldwide; 10th most common cancer [1]
• UK incidence: ~10,300 cases/year
• Sex ratio: Male:Female = 3-4:1
• Peak age: 65-85 years; median age at diagnosis 73 years
• Histology: 90% urothelial (TCC); 5% squamous cell carcinoma; 2% adenocarcinoma; 1-2% small cell
• Main risk factor: Smoking (50% of cases in men, 35% in women) [3]
• Cardinal symptom: Painless visible haematuria (80-90%) [2]
• Stage distribution: ~75% NMIBC, ~25% MIBC at presentation
• 5-year survival: NMIBC > 90%; MIBC 50-60%; metastatic less than 10%

Clinical Pearls

Haematuria = Cancer Until Proven Otherwise: Any adult with visible haematuria requires urgent urology referral and cystoscopy within 2 weeks. Even a single episode matters — bladder cancer can present with intermittent haematuria.

Smoking Is the Single Greatest Risk Factor: Smoking causes 50% of bladder cancers in men and 35% in women. [3] Current smokers have 3-4 times the risk of non-smokers, and the risk persists for 10-20 years after cessation. Risk increases with pack-years and intensity of smoking.

BCG Is the Original Immunotherapy: Intravesical BCG for high-risk NMIBC is one of the oldest and most effective forms of cancer immunotherapy, reducing recurrence by 27% and progression by 37% compared to TURBT alone. [8] Maintenance therapy for up to 3 years is critical for maximum benefit.

CIS Is Deceptively Dangerous: Carcinoma in situ appears flat and red on cystoscopy (easily missed), but is high-grade and carries a 54% risk of progression to muscle-invasive disease if untreated. It requires mandatory BCG therapy.

Neoadjuvant Chemotherapy Is Standard for MIBC: Cisplatin-based neoadjuvant chemotherapy before radical cystectomy improves 5-year overall survival by 5-8% (absolute benefit) and is standard of care for fit patients. [9] Complete pathological response (pT0) is achieved in 25-30% of patients and confers excellent prognosis.

Blue Light Cystoscopy Detects More Tumours: Photodynamic diagnosis with hexaminolevulinate (HAL) increases detection of Ta/T1 tumours by 20% and CIS by 40% compared to white light alone. [10] This leads to a 16% reduction in recurrence at 12 months (NNT = 6).

Why This Matters Clinically

Bladder cancer is common, highly treatable if caught early, but notorious for recurrence and progression. NMIBC requires lifelong surveillance with repeat cystoscopies. MIBC requires aggressive multimodal treatment. Delays in diagnosis worsen prognosis. Early recognition from haematuria investigation, appropriate risk stratification, and adherence to guideline-based surveillance save lives and preserve bladders.

---

2. Epidemiology

Global Burden

Bladder cancer is the 10th most common cancer globally and the 6th most common in men. [1] Age-standardized incidence rates are highest in Southern and Western Europe (23.6 per 100,000 in men) and North America, and lowest in Sub-Saharan Africa and East Asia. Mortality rates have declined in high-income countries due to improved detection and treatment but remain high in low-resource settings.

Incidence & Prevalence

Mortality

• Global deaths: ~213,000/year [1]
• UK deaths: ~5,400/year
• Mortality-to-incidence ratio: ~0.37 (reflects curability of early-stage disease)

Demographics

Risk Factors

Tobacco Smoking

Smoking is the single most important modifiable risk factor, responsible for 50% of cases in men and 35% in women. [3] The carcinogenic aromatic amines and polycyclic aromatic hydrocarbons in tobacco smoke are concentrated in the urine, leading to chronic urothelial exposure and DNA damage.

• Dose-response: Risk increases with pack-years, duration, and intensity
• Reversibility: Risk decreases 30-50% within 4 years of cessation but remains elevated for 10-20 years [3]
• Mechanism: Aromatic amines and polycyclic hydrocarbons in tobacco smoke excreted in urine

Occupational Exposures

Occupational exposures account for 20-25% of cases, particularly in industrialized countries. [11] High-risk industries include dye manufacturing, rubber production, painting, textiles, and chemical production. Latency periods range from 10-30 years from exposure to diagnosis.

• Latency period: 10-30 years from exposure to cancer diagnosis
• UK occupational bladder cancer cases compensable under Industrial Injuries Scheme

Chemical Exposures

Medical Conditions

Genetic Susceptibility

• Family history: 2-fold increased risk if first-degree relative affected
• NAT2 slow acetylator genotype: Impaired detoxification of aromatic amines (2-fold risk in smokers)
• GSTM1 null genotype: Reduced glutathione-S-transferase activity
• Lynch syndrome (hereditary non-polyposis colorectal cancer): Increased urothelial cancer risk

Protective Factors

• High fluid intake (> 2.5 L/day): 50% reduction in risk [12]
• Increased fruit and vegetable consumption: Modest protective effect
• Possible protective effect of vitamin C and selenium (inconsistent evidence)

---

3. Pathophysiology

Molecular Pathogenesis

Bladder cancer arises through two distinct molecular pathways corresponding to NMIBC and MIBC:

Pathway 1: Low-Grade NMIBC (Ta)

• Initiating event: Activating mutations in FGFR3 (fibroblast growth factor receptor 3) — present in 70-80% of low-grade Ta tumours
• Secondary alterations: Loss of chromosome 9, PIK3CA mutations, RAS pathway activation
• Characteristics: Papillary growth, low-grade cytology, frequent recurrence, low progression risk (5-10%)
• Mechanism: Constitutive FGFR3 signaling → increased cell proliferation without invasion

Pathway 2: High-Grade MIBC and CIS

• Initiating event: TP53 mutations (present in 50-70% of MIBC and CIS)
• Secondary alterations: RB1 loss, CDKN2A deletion, MDM2 amplification, ERBB2 amplification
• Characteristics: High-grade cytology, invasive growth, high progression risk (50-70% for CIS/T1)
• Mechanism: Loss of p53 tumor suppressor → genomic instability, invasion, and metastasis

Molecular Subtypes (Consensus Classification)

Molecular profiling identifies distinct subtypes with prognostic and therapeutic implications. [6] The consensus classification identifies five major subtypes based on transcriptomic profiling and mutational landscape:

• Clinical utility: Basal tumours show greater response to neoadjuvant chemotherapy (30-40% pathological complete response); luminal tumours may benefit from FGFR inhibitors (erdafitinib)
• Biomarker development: PD-L1 expression (CPS ≥10 or IC ≥5%) and tumor mutational burden predict immunotherapy response. High TMB correlates with improved response to checkpoint inhibitors. [13]

Histological Types

Variant Histologies in Urothelial Carcinoma

Staging (TNM 8th Edition)

T Stage (Primary Tumour)

N Stage (Regional Lymph Nodes)

M Stage (Distant Metastasis)

Classification: NMIBC vs MIBC

Risk Stratification for NMIBC (EAU 2024 Guidelines)

Risk stratification determines intensity of intravesical therapy and surveillance.

Key prognostic factors: Grade, stage, size, multifocality, recurrence rate, CIS presence, lymphovascular invasion

---

4. Clinical Presentation

Symptoms

Haematuria Characteristics

• Painless: Key differentiating feature from UTI, stones (painful)
• Intermittent: May occur once and resolve for weeks/months
• Total haematuria: Present throughout urinary stream (vs. initial = urethra; terminal = bladder/prostate)
• Clot formation: Heavy bleeding can cause clot retention and acute urinary retention

Signs

In most cases of NMIBC, physical examination is normal. Signs appear with advanced disease:

Abdominal Examination:

• Palpable bladder (clot retention, outlet obstruction)
• Suprapubic tenderness (rare)
• Palpable flank mass (hydronephrosis, large upper tract tumour)

Digital Rectal Examination (males):

• Palpable bladder mass (anterior, bimanual examination)
• Pelvic sidewall fixation (T4 disease)
• Prostatic abnormality (prostatic stromal invasion)

Pelvic Examination (females):

• Vaginal involvement (T4a)
• Palpable pelvic mass

General Examination:

• Pallor (chronic anaemia from haematuria or bone marrow infiltration)
• Cachexia (metastatic disease)
• Peripheral lymphadenopathy (supraclavicular nodes — Virchow's node)
• Lower limb oedema (pelvic/iliac lymph node obstruction)
• Bone tenderness (skeletal metastases)

Red Flags — Urgent Referral Criteria

[!CAUTION] Immediate 2-Week Wait Urology Referral (UK NICE NG12):

• Age ≥45 with unexplained visible haematuria (even single episode)
• Age ≥60 with non-visible haematuria plus dysuria or raised WBC on urine dipstick
• Age ≥60 with recurrent or persistent UTI

Additional Red Flags:

• Hydronephrosis on imaging (suggests ureteric obstruction)
• Palpable abdominal or pelvic mass
• Unexplained weight loss with urinary symptoms
• Persistent lower urinary tract symptoms in older adults (> 60) with smoking history

---

5. Clinical Examination

Structured Approach

1. General Inspection

• Pallor: Anaemia from chronic blood loss or bone marrow infiltration
• Cachexia: Advanced/metastatic disease
• Performance status: ECOG 0-4 assessment (determines fitness for chemotherapy/surgery)

2. Abdominal Examination

• Inspection: Distension (clot retention), previous surgical scars
• Palpation:
  • Palpable bladder (suprapubic dullness, clot retention, large tumour)
  • Palpable kidneys (bilateral hydronephrosis)
  • Hepatomegaly (metastatic disease)
• Percussion: Dullness over distended bladder
• Auscultation: Bowel sounds (ileus if ureteric obstruction)

3. Bimanual Pelvic Examination

Males (DRE):

• Technique: Patient in left lateral position; assess prostate, bladder base
• Findings:
  • Palpable bladder tumour (anterior mass)
  • Pelvic sidewall fixation (T4b — unresectable)
  • Prostatic involvement (asymmetry, nodularity)

Females (Vaginal examination):

• Findings: Vaginal wall involvement (T4a), pelvic mass, cervical involvement

4. Lymph Node Examination

• Supraclavicular: Virchow's node (left supraclavicular) — metastatic spread
• Inguinal: Rare; suggests urethral or anterior urethral involvement

5. Extremities

• Lower limb oedema: Bilateral (IVC obstruction, hypoalbuminemia), unilateral (iliac vein compression)
• Bone tenderness: Lumbar spine, pelvis (metastases)

---

6. Investigations

Diagnostic Pathway for Haematuria

         VISIBLE HAEMATURIA
                 ↓
    ┌────────────────────────┐
    │ 1. URGENT REFERRAL     │
    │    (2-week wait)       │
    └────────────────────────┘
                 ↓
    ┌────────────────────────┐
    │ 2. INITIAL ASSESSMENT  │
    │  - Urine dipstick      │
    │  - Urine cytology      │
    │  - FBC, U&E            │
    │  - Exclude UTI         │
    └────────────────────────┘
                 ↓
    ┌────────────────────────┐
    │ 3. IMAGING             │
    │  - CT urogram (gold)   │
    │  - OR USS KUB          │
    └────────────────────────┘
                 ↓
    ┌────────────────────────┐
    │ 4. CYSTOSCOPY          │
    │  - Flexible (clinic)   │
    │  - ± Biopsy if lesion  │
    └────────────────────────┘
                 ↓
         TUMOUR SEEN?
        /            \
      YES             NO
       ↓               ↓
    TURBT      CT urogram normal
  (diagnostic +    & cystoscopy
   therapeutic)    normal?
                      ↓
                 Discharge with
                 safety-netting

First-Line Investigations

Urine Cytology

• Sensitivity: 50% for low-grade Ta; 80-90% for high-grade and CIS
• Specificity: 95%
• Limitations: Cannot distinguish Ta from T1/T2; low sensitivity for low-grade tumours
• Optimal use: Second-void morning urine (avoids degenerative changes from overnight stasis)
• Role: Particularly useful for CIS detection (flat lesion, easily missed on white-light cystoscopy)

Urinary Biomarkers (Emerging)

Current role: Adjunct to cytology, not replacements. Useful in surveillance settings to reduce cystoscopy burden.

Imaging

CT Urogram (CTU)

Gold standard for haematuria investigation.

Protocol:

• Non-contrast phase (stones, calcification)
• Arterial phase (renal masses)
• Nephrographic phase (renal parenchyma)
• Excretory phase (10 min post-contrast; opacifies collecting system, ureters, bladder)

Findings in Bladder Cancer:

• Bladder wall thickening or mass (irregular, enhancing)
• Filling defects in bladder
• Hydronephrosis (ureteric obstruction)
• Upper tract urothelial tumours (5% synchronous)
• Lymphadenopathy (iliac, para-aortic nodes)
• Metastases (lung, liver, bone)

Sensitivity: 85-95% for bladder masses > 5 mm Limitations: Cannot assess depth of invasion or distinguish Ta from T1/T2

Ultrasound (USS)

Indications: Contraindication to CT contrast (renal failure, allergy)

Findings:

• Bladder wall thickening (> 5 mm when distended)
• Polypoid mass (hypoechoic)
• Hydronephrosis

Limitations: Operator-dependent; poor sensitivity for small (less than 1 cm) or flat (CIS) lesions

MRI Pelvis

Indications:

• MIBC staging (T2-T4) — assesses depth of invasion
• Evaluation of prostatic/urethral involvement
• Young patients (avoid radiation)

T2-weighted sequences:

• Low signal in muscle (disruption = invasion)
• High signal in perivesical fat (T3 disease)

Diffusion-weighted imaging (DWI):

• Restricted diffusion in tumour (high signal on DWI, low on ADC)

Accuracy: T-staging 85-90%; N-staging 70-75%

PET-CT

Indications:

• Node-positive or metastatic disease staging
• Assessment of residual disease post-neoadjuvant chemotherapy
• Surveillance in high-risk patients

Tracer: 18F-FDG

Utility:

• Sensitivity for lymph node metastases: 60-75%
• Detection of occult metastases (changes management in 15-20%)

Limitations: False positives (inflammation, infection); false negatives (small volume disease)

Cystoscopy

Flexible Cystoscopy (Outpatient)

Indications:

• All patients with haematuria
• Surveillance after TURBT

Technique:

• Local anaesthetic gel (lidocaine 2%)
• Flexible cystoscope via urethra
• Systematic bladder inspection (trigone, lateral walls, dome, ureteric orifices)

Findings:

• Papillary tumour: Frond-like, exophytic, most common appearance
• Sessile tumour: Broad-based, solid mass (suggests muscle invasion)
• CIS: Flat, red, velvety patch (easily missed on white light)

Advantages: Outpatient, well-tolerated, immediate diagnosis Limitations: Cannot resect tumours or obtain deep biopssy

Rigid Cystoscopy + TURBT (Theatre)

Indications:

• Tumour identified on flexible cystoscopy
• Diagnostic and therapeutic

Technique:

• General or spinal anaesthesia
• Systematic resection of tumour in fragments
• Separate deep biopsy to include detrusor muscle (critical for staging)
• Coagulation of tumour base

Histological requirements:

• Presence of detrusor muscle in specimen (confirms adequacy of resection and allows distinction between T1 and T2)
• Absence of muscle = incomplete staging → repeat TURBT in 2-6 weeks (mandatory for high-grade T1)

Blue Light Cystoscopy (Photodynamic Diagnosis)

Mechanism:

• Intravesical instillation of hexaminolevulinate (HAL) or 5-aminolevulinic acid (5-ALA) 1-3 hours pre-procedure
• Preferentially accumulates in malignant cells → produces protoporphyrin IX
• Blue light (380-440 nm) excitation → red fluorescence in tumour

Evidence: [10]

• Increases detection of Ta/T1 tumours by 20%
• Increases detection of CIS by 40%
• Reduces recurrence at 12 months by 16% (NNT = 6)
• Particularly beneficial in high-risk NMIBC where CIS detection is critical

Indications:

• High-risk NMIBC
• Suspected CIS
• Positive cytology with negative white-light cystoscopy

Limitations: False positives (inflammation, BCG cystitis)

Biopsy and Histopathology

TURBT Specimen Requirements

1. Tumour fragments (papillary component)
2. Detrusor muscle in separate specimen (proves depth of resection)
3. Separate biopsies from:
   • Random bladder biopsies (if +ve cytology, no visible tumour)
   • Prostatic urethra (males with bladder neck/trigone tumours or CIS)

Histopathology Report Must Include:

Re-Resection TURBT (Second-Look TURBT)

Indications (mandatory):

• High-grade T1 disease
• Incomplete initial resection
• No detrusor muscle in initial specimen
• Large tumours (> 3 cm)

Timing: 2-6 weeks after initial TURBT

Findings:

• Residual tumour in 30-50% of cases
• Upstaging to T2 in 5-10% of presumed T1

---

7. Management

Overview of Treatment Strategy

               BLADDER CANCER DIAGNOSIS
                        ↓
               ┌────────┴─────────┐
               │      TURBT       │
               │  (all patients)  │
               └────────┬─────────┘
                        ↓
          ┌─────────────┴──────────────┐
          │                            │
       NMIBC                         MIBC
    (Ta, Tis, T1)                   (≥T2)
          │                            │
          ↓                            ↓
   ┌──────┴──────┐          ┌─────────┴──────────┐
   │             │          │                    │
  Low      Intermediate   High              Fitness
  risk        risk        risk            assessment
   │             │          │                    │
   ↓             ↓          ↓           ┌────────┴────────┐
 TURBT    TURBT + MMC   TURBT + BCG     │                 │
  only      (1 year)   (3 years)      FIT              UNFIT
   │             │          │            │                 │
   ↓             ↓          ↓            ↓                 ↓
Surveillance Surveillance  ├─→ Response  Neoadjuvant     Trimodal
 (yearly)   (3-monthly)    │             chemo +         therapy OR
                           │             radical       palliative
                           │             cystectomy     chemo/RT
                           │
                           └─→ BCG failure
                               → Consider early
                                  cystectomy

NMIBC Management (Ta, Tis, T1)

Low-Risk NMIBC

Definition: Single Ta, low-grade, less than 3 cm, no CIS

Treatment:

1. Complete TURBT
2. Single immediate postoperative intravesical chemotherapy:
   • Mitomycin C 40 mg in 40 mL saline, instilled within 24 hours (ideally within 6 hours) of TURBT
   • Retained in bladder for 60 minutes
   • Reduces recurrence by 12% (absolute risk reduction) [14]
   • Contraindicated if bladder perforation suspected
   • Mechanism: Ablates circulating tumor cells implanted during resection

Surveillance:

• Cystoscopy at 3 months and 12 months
• If clear at 12 months → yearly cystoscopy for 5 years
• Consider discharge after 5 years if no recurrence

Intermediate-Risk NMIBC

Definition: Recurrent or multifocal Ta low-grade, OR single Ta high-grade less than 3 cm

Treatment:

1. Complete TURBT ± re-resection if incomplete
2. Induction intravesical therapy:
   • Option 1: Mitomycin C 40 mg weekly × 6 weeks
   • Option 2: BCG (one-third to full dose) weekly × 6 weeks
3. Maintenance therapy (if BCG used): 3-weekly courses at 3, 6, 12 months

Surveillance:

• Cystoscopy + cytology at 3, 6, 12 months, then yearly for 5 years
• Consider upper tract imaging (CT urogram) if high-grade

High-Risk NMIBC

Definition: T1, OR high-grade Ta, OR CIS, OR multiple/recurrent high-grade, OR variant histology

Treatment:

1. Complete TURBT
2. Mandatory re-resection TURBT at 2-6 weeks (especially for T1)
3. BCG induction + maintenance:
   • Induction: BCG (one-third to full dose) weekly × 6 weeks, starting 2-4 weeks after (re-)TURBT
   • Maintenance: [8]
     • SWOG regimen (most evidence): 3-weekly BCG at 3, 6, 12, 18, 24, 30, 36 months
     • Reduces recurrence by 27% and progression by 37% vs. TURBT alone
     • Full 3-year course associated with best outcomes
     • Early discontinuation (e.g., after 1 year) reduces benefit significantly

BCG Failure Definitions:

• BCG-refractory: Persistent high-grade disease at 6 months despite adequate BCG
• BCG-relapsing: Recurrence of high-grade disease after initial complete response
• BCG-unresponsive: Persistent or recurrent high-grade disease at 6 months (FDA definition)

Management of BCG Failure:

• First-line: Radical cystectomy (recommended before progression to MIBC) - preferred for fit patients
• Bladder-preservation alternatives (selected patients):
  • Pembrolizumab (FDA-approved for BCG-unresponsive CIS) [15]
  • Sequential intravesical gemcitabine + docetaxel
  • Clinical trials (nadofaragene firadenovec gene therapy, N-803 + BCG)
  • Response rates 20-40%, but cystectomy remains gold standard

Surveillance:

• Intensive: Cystoscopy + cytology every 3 months for 2 years, then every 6 months to 5 years, then yearly
• Upper tract imaging (CT urogram) at 1-2 years, then as indicated
• Consider urine biomarkers (NMP22, UroVysion FISH) to reduce cystoscopy burden

Very High-Risk NMIBC

Definition: T1 high-grade + concurrent CIS, OR variant histology (micropapillary, plasmacytoid), OR lymphovascular invasion, OR prostatic urethral CIS, OR recurrent T1 high-grade

Treatment:

• Consider early radical cystectomy (preferred option due to 50-70% progression risk)
• BCG induction + maintenance acceptable if patient declines surgery or unfit

BCG Therapy: Practical Considerations

Mechanism: Live attenuated Mycobacterium bovis → local immune activation (Th1 cytokines, cytotoxic T cells) → tumour destruction

Dose:

• Standard: 81 mg (Connaught strain) or 120 mg (TICE strain)
• One-third dose as effective with fewer side effects in some studies

Contraindications:

• Active UTI (defer until treated)
• Traumatic catheterization (risk of BCG sepsis)
• Immunosuppression (HIV, chemotherapy, biologics)
• Pregnancy

Side Effects:

BCG Shortage Considerations:

• Due to global shortages, prioritize for highest-risk patients (T1 high-grade, CIS)
• Consider sequential gemcitabine + docetaxel for intermediate-risk if BCG unavailable

---

MIBC Management (≥T2)

Fitness Assessment

Cisplatin eligibility (critical for neoadjuvant chemotherapy):

• ECOG performance status 0-1
• eGFR ≥60 mL/min
• No NYHA class III-IV heart failure
• No significant hearing impairment
• No peripheral neuropathy

Surgical fitness (for radical cystectomy):

• Cardiopulmonary reserve (CPEX testing if borderline)
• No uncontrolled comorbidities
• Ability to tolerate major surgery (4-6 hour operation)

Treatment Pathway for Fit Patients

      MIBC (cT2-T4a N0 M0)
              ↓
    ┌─────────────────────┐
    │  Staging CT/MRI     │
    │  Fitness assessment │
    └─────────────────────┘
              ↓
       Cisplatin-fit?
        ╱          \
      YES            NO
       ↓              ↓
 Neoadjuvant     Upfront RC
 chemotherapy    (consider
 (4 cycles)      carboplatin
       ↓          regimen)
 Radical              ↓
 cystectomy      Adjuvant
 + PLND          chemo if
       ↓          pT3/N+
 Adjuvant
 chemo if
 residual pT3+/N+

Neoadjuvant Chemotherapy

Evidence: Meta-analysis of 11 RCTs (3,005 patients) shows 5-8% absolute improvement in 5-year overall survival with platinum-based neoadjuvant chemotherapy. [9] This translates to approximately 1 life saved for every 13-20 patients treated (NNT = 13-20).

Standard regimens:

Timing:

• 4 cycles pre-cystectomy
• Surgery within 4-8 weeks of completing chemotherapy

Pathological response:

• Complete response (pT0): 25-30% → excellent prognosis (70% 5-year survival)
• Partial response: 40%
• No response: 30%

Contraindications (carboplatin-based regimens instead):

• eGFR less than 60 mL/min
• Significant hearing loss
• Neuropathy

Radical Cystectomy

Procedure:

Males:

• Radical cystoprostatectomy: Bladder + prostate + seminal vesicles + distal ureters
• Pelvic lymph node dissection (obturator, internal/external iliac, presacral nodes)

Females:

• Anterior pelvic exenteration: Bladder + uterus + ovaries + anterior vaginal wall + urethra + distal ureters
• Pelvic lymph node dissection

Urinary Diversion Options:

Extended lymph node dissection: Up to aortic bifurcation in high-risk (improves staging; possible therapeutic benefit)

Perioperative outcomes:

• Median hospital stay: 10-14 days
• 90-day mortality: 2-3% (high-volume centers)
• Morbidity: 50-60% (Clavien-Dindo grade I-V)

Complications of Radical Cystectomy

Adjuvant Chemotherapy

Indications:

• Pathological stage pT3-pT4 or pN+ disease after radical cystectomy
• No neoadjuvant chemotherapy given pre-operatively

Evidence: Weaker than neoadjuvant (less well-tolerated post-operatively, delayed recovery)

Regimen: Same as neoadjuvant (GC or ddMVAC) × 4 cycles

Timing: Within 90 days of surgery (if recovery permits)

---

Bladder-Preserving Trimodal Therapy

Indications:

• Patients unfit for or declining radical cystectomy
• Solitary T2 tumours less than 5 cm
• No hydronephrosis or extensive CIS
• Normal bladder function

Components:

1. Maximal TURBT (complete visible tumour resection)
2. Concurrent chemoradiotherapy:
   • Radiotherapy: 64-66 Gy in 32-33 fractions over 6-7 weeks
   • Chemotherapy: Cisplatin (weekly) or 5-FU + mitomycin C

Outcomes:

• 5-year overall survival: 50-60% (comparable to cystectomy in selected patients)
• Bladder preservation: 60-70% at 5 years
• Salvage cystectomy: Required in 30-40% for recurrence or progression

Surveillance: Intensive cystoscopy every 3 months for 2 years

---

Advanced and Metastatic Bladder Cancer

First-Line Systemic Therapy (Metastatic or Unresectable)

Cisplatin-Eligible Patients:

Standard: Enfortumab vedotin + Pembrolizumab (EV-302 trial) [7]

• Median OS: 31.5 months (vs. 16.1 months with chemotherapy alone) - HR 0.47, pless than 0.001
• Median PFS: 12.5 months (vs. 6.3 months) - HR 0.45, pless than 0.001
• Overall response rate: 68% vs 44%
• FDA/EMA approved 2024 as first-line therapy
• Represents paradigm shift from chemotherapy-first approach

Alternative: Gemcitabine-Cisplatin (GC)

• Median OS: 14-16 months
• Response rate: 50%

Cisplatin-Ineligible Patients:

Standard: Enfortumab vedotin + Pembrolizumab

Alternatives:

• Carboplatin + gemcitabine: Median OS 9-10 months (inferior to cisplatin-based)
• Pembrolizumab monotherapy (if PD-L1 CPS ≥10): Median OS 11-12 months

Second-Line and Beyond

After Platinum Chemotherapy:

Enfortumab Vedotin:

• Mechanism: Antibody-drug conjugate (ADC) targeting Nectin-4 (expressed in 95% of urothelial cancers) → delivers monomethyl auristatin E (MMAE) cytotoxic payload
• Dosing: 1.25 mg/kg IV D1, D8, D15 of 28-day cycle
• Toxicity: Peripheral neuropathy (50%), rash (50%), hyperglycemia (10%)

PD-1/PD-L1 Checkpoint Inhibitors:

• Mechanism: Block PD-1/PD-L1 interaction → restore T-cell mediated anti-tumour immunity
• Biomarker: PD-L1 expression (CPS ≥10 or IC ≥5%) predicts higher response rates
• Durable responses: 20-30% of responders have ongoing responses > 2 years

FGFR Inhibitors (Erdafitinib):

• Indication: FGFR2/3 mutations or fusions detected by NGS or FISH (present in ~20% of patients) [18]
• Response rate: 40%
• Toxicity: Hyperphosphatemia (requires dietary restriction), dry eyes, nail changes, stomatitis
• Mechanism: Selective pan-FGFR kinase inhibitor blocking oncogenic FGFR signaling

Palliative Care Integration

• Early palliative care referral improves quality of life and may extend survival
• Symptom management: Pain (opioids), haematuria (tranexamic acid, bladder irrigation), urinary obstruction (nephrostomy)
• Psychosocial support, advanced care planning

---

8. Surveillance and Follow-Up

NMIBC Surveillance Protocols

Lifelong surveillance is mandatory due to high recurrence risk (50-70% at 5 years).

Cystoscopy:

• Flexible cystoscopy + urine cytology
• Consider blue-light cystoscopy for high-risk patients

Upper Tract Surveillance (high-risk patients):

• CT urogram at 1-2 years, then as clinically indicated
• Risk of upper tract recurrence: 2-4% in NMIBC, 7-10% in high-risk

MIBC Post-Cystectomy Surveillance

First 2 Years (highest recurrence risk):

• CT chest/abdomen/pelvis every 3-6 months
• U&E, creatinine (monitor renal function, metabolic acidosis)
• Vitamin B12 levels (if ileal conduit)

Years 3-5:

• CT chest/abdomen/pelvis every 6-12 months

After 5 Years:

• Yearly imaging as clinically indicated
• Lifelong monitoring of renal function and electrolytes

Sites of Recurrence:

• Lung (35%), liver (20%), bone (15%), lymph nodes (40%)
• Median time to recurrence: 12 months (80% within 2 years)

---

9. Complications

Disease-Related Complications

Treatment-Related Complications

BCG Therapy Complications

Radical Cystectomy Complications

Early (less than 30 days):

• Ileus (20-25%)
• Infection (wound, UTI, pneumonia) (20-30%)
• VTE (5%)
• Anastomotic leak (3-5%)
• MI, stroke, death (2-3%)

Late (> 30 days):

• Metabolic acidosis (10-15%)
• Vitamin B12 deficiency (15-20%)
• Ureteroileal stricture (5-10%)
• Stomal complications (stenosis, hernia, prolapse) (20-30%)
• Sexual dysfunction (erectile dysfunction in 80-90% males; dyspareunia in females)
• Incontinence (neobladder: 20% daytime, 50% nighttime)

Chemotherapy Complications

---

10. Prognosis & Outcomes

Survival by Stage

Recurrence Rates (NMIBC)

• Low-risk: 15% at 1 year, 30-40% at 5 years
• Intermediate-risk: 40% at 1 year, 50-60% at 5 years
• High-risk: 60% at 1 year, 70-80% at 5 years (despite BCG)

Progression to MIBC (NMIBC)

• Low-risk: less than 1% at 5 years
• Intermediate-risk: 5% at 5 years
• High-risk: 25-50% at 5 years (without adequate BCG therapy)
• Very high-risk: 50-70% at 5 years

Prognostic Factors

Quality of Life After Cystectomy

• Ileal conduit: Adaptation to stoma; body image concerns; overall QoL comparable to age-matched controls by 12 months
• Neobladder: Better body image but continence issues (20% daytime, 50% nighttime incontinence); requires CIC in 15-20%
• Sexual function: Erectile dysfunction in 80-90% males (nerve-sparing reduces to 40-60%); dyspareunia in females

---

11. Evidence & Guidelines

Key Guidelines

1. NICE NG2: Bladder cancer: diagnosis and management (2015, updated 2023)

   • UK national guideline for diagnosis, treatment, surveillance
   • nice.org.uk/guidance/ng2

2. EAU Guidelines on Non-Muscle-Invasive Bladder Cancer (2024)

   • European Association of Urology; annual updates
   • Risk stratification, BCG protocols, surveillance
   • uroweb.org/guidelines

3. EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer (2024)

   • Neoadjuvant chemotherapy, cystectomy, trimodal therapy, systemic therapy

4. NCCN Guidelines: Bladder Cancer (Version 3.2024)

   • USA National Comprehensive Cancer Network
   • nccn.org

5. AUA/SUO Guidelines on Non-Muscle Invasive Bladder Cancer (2024)

   • American Urological Association / Society of Urologic Oncology
   • auanet.org

Landmark Trials

NMIBC

Sylvester et al., Lancet Oncol 2010 [8]

• Meta-analysis: BCG maintenance (SWOG regimen) reduces recurrence by 27% and progression by 37%
• PMID: 20207596
• Demonstrates importance of full 3-year maintenance for maximum benefit

Sylvester et al., Eur Urol 2016 [14]

• Meta-analysis: Single immediate postoperative intravesical chemotherapy reduces recurrence by 12% (absolute)
• PMID: 26091833
• Mitomycin C most commonly used agent

Burger et al., Eur Urol 2013 (Hexvix study) [10]

• Blue-light cystoscopy increases detection of Ta/T1 by 20% and CIS by 40%
• PMID: 22877502
• Reduces 12-month recurrence rate by 16% (NNT = 6)

MIBC

Grossman et al., NEJM 2003 (SWOG 8710) [9]

• Neoadjuvant MVAC chemotherapy improves median survival from 46 to 77 months
• PMID: 12915604
• Established neoadjuvant chemotherapy as standard of care for MIBC

Advanced Bladder Cancer Meta-Analysis Collaboration, Lancet 2005

• Meta-analysis: Neoadjuvant platinum-based chemotherapy improves 5-year OS by 5-8% (absolute)
• PMID: 15823385

Advanced/Metastatic

Powles et al., NEJM 2024 (EV-302) [7]

• Enfortumab vedotin + pembrolizumab vs. chemotherapy: Median OS 31.5 vs. 16.1 months (HR 0.47)
• PMID: 38446675
• Landmark trial establishing EV+pembro as new first-line standard

Bellmunt et al., NEJM 2017 (KEYNOTE-045) [17]

• Pembrolizumab superior to chemotherapy in platinum-refractory disease: OS 10.3 vs. 7.4 months
• PMID: 28212060
• First checkpoint inhibitor to demonstrate OS benefit in bladder cancer

Powles et al., NEJM 2021 (EV-301) [12]

• Enfortumab vedotin vs. chemotherapy: Median OS 12.9 vs. 9 months (HR 0.70)
• PMID: 27013195

Evidence Levels

---

12. Recent Advances (2023-2025)

Emerging Therapies

1. Enfortumab Vedotin + Pembrolizumab First-Line (2024) [3]

   • FDA/EMA approval as first-line therapy for metastatic urothelial cancer
   • Paradigm shift: Immunotherapy + ADC superior to chemotherapy

2. Durvalumab Adjuvant Therapy (IMvigor010)

   • Adjuvant checkpoint inhibitor post-cystectomy in high-risk patients
   • Mixed results; not yet standard of care

3. TAR-200 (Targeted Release Gemcitabine)

   • Intravesical sustained-release gemcitabine device
   • Phase 3 trials ongoing for high-risk NMIBC

4. Nadofaragene Firadenovec (Adstiladrin)

   • Gene therapy: Adenovirus vector delivering interferon α-2b
   • FDA-approved for BCG-unresponsive NMIBC with CIS (2022)

5. Erdafitinib (FGFR Inhibitor)

   • Targeting FGFR2/3 alterations (20% of advanced urothelial cancers)
   • Response rate 40%; durable responses

Molecular Profiling

• Tumor Mutational Burden (TMB): Predicts immunotherapy response
• PD-L1 Expression: CPS ≥10 associated with higher checkpoint inhibitor efficacy
• FGFR Alterations: Predict erdafitinib response
• HER2 Expression: Emerging target (trastuzumab deruxtecan in trials)

Artificial Intelligence

• AI-assisted cystoscopy: Real-time detection of bladder tumours (sensitivity > 95%)
• Radiomics: CT-based texture analysis predicts MIBC response to neoadjuvant chemotherapy

---

13. Patient/Layperson Explanation

What is Bladder Cancer?

Bladder cancer is when abnormal cells grow in the lining of your bladder — the organ that stores urine before you pass it out. The most common type is called urothelial carcinoma (or transitional cell carcinoma), which starts in the cells lining the inside of the bladder.

What Causes It?

• Smoking is the biggest risk factor — it causes about half of all bladder cancers
• Some chemicals used in certain industries (dyes, rubber, paints)
• Age (more common over 65)
• Being male (men are 3-4 times more likely to get it than women)

What Are the Symptoms?

The most important warning sign is blood in your urine (haematuria):

• Usually painless
• May happen once and then go away for weeks (but still needs checking)
• Urine may look pink, red, or cola-colored

Other symptoms:

• Needing to urinate more often
• Pain or burning when urinating
• Feeling the need to urinate but nothing comes out

How is it Diagnosed?

1. Urine test: To confirm blood and rule out infection
2. CT scan: Takes pictures of your bladder and kidneys
3. Cystoscopy: A thin camera is passed through your urethra to look inside your bladder (done under local anaesthetic in clinic, or under general anaesthetic if a tumour is found)

How is it Treated?

Treatment depends on whether the cancer has invaded the muscle layer of the bladder:

Non-Muscle-Invasive Bladder Cancer (75% of cases)

• The tumour is removed through a telescope (TURBT — transurethral resection of bladder tumour)
• Medicine is then put directly into the bladder to reduce the chance of it coming back:
  • Mitomycin C (chemotherapy) for lower-risk cancers
  • BCG (a vaccine that activates the immune system) for higher-risk cancers
• You'll need regular cystoscopy check-ups (every 3-12 months depending on risk)

Muscle-Invasive Bladder Cancer (25% of cases)

This is more serious and requires major treatment:

Option 1: Surgery to Remove the Bladder (Radical Cystectomy)

• The entire bladder is removed
• A new way to store and pass urine is created:
  • "Ileal conduit: A bag on your tummy (urostomy)"
  • "Neobladder: A new bladder made from your intestine (you urinate normally through your urethra, but may need to use a catheter)"
• Chemotherapy is usually given before surgery to shrink the tumour and improve cure rates

Option 2: Radiotherapy + Chemotherapy (Bladder-Preserving)

• If you can't have surgery or want to keep your bladder
• 6-7 weeks of daily radiotherapy combined with chemotherapy
• The bladder is preserved in 60-70% of patients

Advanced or Metastatic Bladder Cancer

• Chemotherapy (gemcitabine + cisplatin)
• Immunotherapy (pembrolizumab, atezolizumab) — helps your immune system fight the cancer
• Enfortumab vedotin — a newer targeted drug that delivers chemotherapy directly to cancer cells

What to Expect

• Early bladder cancer (non-muscle-invasive) has excellent survival rates (> 90% at 5 years), but it often comes back, so lifelong check-ups are needed
• Muscle-invasive cancer is more serious, but with surgery and chemotherapy, 50-60% of people are cured
• Advanced cancer is harder to cure, but new immunotherapy treatments are helping people live longer

When to See a Doctor

See a doctor urgently if you notice:

• Blood in your urine (even once, even if it goes away)
• Persistent pain when urinating (especially if over 60 and you smoke)
• Urinary symptoms that don't get better with antibiotics

Living with Bladder Cancer

• If you've had bladder cancer, you'll need regular cystoscopy check-ups for many years
• If your bladder was removed, you'll adjust to a urostomy bag or learn to use a catheter if you have a neobladder
• Stop smoking (if you smoke) — it reduces the chance of cancer coming back
• Drink plenty of fluids

---

14. References

Primary Guidelines

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. PMID: 33538338 DOI: 10.3322/caac.21660

2. Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol. 2013;63(2):234-241. PMID: 22877502 DOI: 10.1016/j.eururo.2012.07.033

3. Powles T, Valderrama BP, Gupta S, et al. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer (EV-302). N Engl J Med. 2024;390(10):875-888. PMID: 38446675 DOI: 10.1056/NEJMoa2312117

4. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964-1970. PMID: 12394686 DOI: 10.1016/S0022-5347(05)64273-5

5. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer (SWOG 8710). N Engl J Med. 2003;349(9):859-866. PMID: 12915604 DOI: 10.1056/NEJMoa022148

6. Burger M, Grossman HB, Droller M, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013;64(5):846-854. PMID: 23602406 DOI: 10.1016/j.eururo.2013.03.059

7. Cumberbatch MG, Cox A, Teare D, Catto JW. Contemporary Occupational Carcinogen Exposure and Bladder Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2015;1(9):1282-1290. PMID: 26448565 DOI: 10.1001/jamaoncol.2015.3209

8. Ros MM, Bas Bueno-de-Mesquita HB, Büchner FL, et al. Fluid intake and the risk of urothelial cell carcinomas in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer. 2011;128(11):2695-2708. PMID: 20715171 DOI: 10.1002/ijc.25592

9. Kamoun A, de Reyniès A, Allory Y, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2020;77(4):420-433. PMID: 31563503 DOI: 10.1016/j.eururo.2019.09.006

10. Sylvester RJ, Oosterlinck W, Holmang S, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder. Eur Urol. 2016;69(2):231-244. PMID: 26091833 DOI: 10.1016/j.eururo.2015.05.050

11. Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22(7):919-930. PMID: 34143971 DOI: 10.1016/S1470-2045(21)00147-9

12. Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma (EV-301). N Engl J Med. 2021;384(12):1125-1135. PMID: 33577729 DOI: 10.1056/NEJMoa2035807

13. Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-045). N Engl J Med. 2017;376(11):1015-1026. PMID: 28212060 DOI: 10.1056/NEJMoa1613683

14. National Institute for Health and Care Excellence (NICE). Bladder cancer: diagnosis and management (NG2). 2015 (updated 2023). nice.org.uk/guidance/ng2

15. Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and CIS). Eur Urol. 2022;81(1):75-94. PMID: 34511303 DOI: 10.1016/j.eururo.2021.08.010

16. Witjes JA, Bruins HM, Cathomas R, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer. Eur Urol. 2021;79(1):82-104. PMID: 33153729 DOI: 10.1016/j.eururo.2020.03.055

17. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur Urol. 2005;48(2):202-205. PMID: 15823385 DOI: 10.1016/j.eururo.2005.04.006

18. Gontero P, Sylvester R, Pisano F, et al. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin. BJU Int. 2016;118(1):44-52. PMID: 26991759 DOI: 10.1111/bju.13354

19. Loriot Y, Necchi A, Park SH, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma (BLC2001). N Engl J Med. 2019;381(4):338-348. PMID: 31340094 DOI: 10.1056/NEJMoa1817323

20. Kamat AM, Sylvester RJ, Böhle A, et al. Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. J Clin Oncol. 2016;34(16):1935-1944. PMID: 26811532 DOI: 10.1200/JCO.2015.64.4070

Further Resources

• Bladder Cancer UK: bladdercanceruk.org
• Action Bladder Cancer UK (ABC UK): actionbladdercanceruk.org
• Macmillan Cancer Support: macmillan.org.uk
• Bladder Cancer Advocacy Network (BCAN): bcan.org (USA)

---

Last Reviewed: 2026-01-11 | MedVellum Editorial Team

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists and adhere to local/national guidelines.